First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response

A study published in the main medical journal The Lancet states that the first COVID-19 vaccine achieved promising results in the first phase of human clinical trials. The study revealed that the vaccine released neutral antibodies that could effectively fight the virus in humans. Tea cells in the immune system that play a key role in preventing the virus have responded effectively. Initially, the vaccine was launched on 108 people. They said they saw the results 28 days after vaccination.

However, scientists from the Beijing Biotechnology Institute believe that more research is needed before the vaccine can protect humans from any viruses. However, they argue that the immune system's reactions to these vaccines will certainly not leave people with COVID-19.

Human trial of COVID-19 vaccine finds it is safe and induces rapid immune response

The vaccine was administered to 108 people aged between 18 and 60 years. They have been vaccinated in various doses. They often checked their blood samples. Antibodies that play a key role in virus prevention and T cell response. Researchers said that no major adverse effects were observed in those who received the vaccine.

BEFORE BUYING HOME INSPECTION CHECKLIST